GLPBio

Ganoderic Acid A

Catalog No.: GN10109Purity:>98.00%
COASDSData Sheet
Ganoderic Acid A is a triterpenoid compound derived from Ganoderma lucidumand exhibits multiple biological activities.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.

Ganoderic Acid A
Cas No.: 81907-62-2
10mM (in 1mL DMSO)In Stock
$97.00
1
1mgIn Stock
$35.00
1
5mgIn Stock
$88.00
1
10mgIn Stock
$140.00
1
25mgIn Stock
$224.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

Ganoderic Acid A is a triterpenoid compound derived from Ganoderma lucidumand exhibits multiple biological activities[1-2]. Ganoderic Acid A possesses inhibitory effects against cancer, oxidation, and aging, among others[3-4].

In vitro, concurrent treatment of BV2 microglial cells with Ganoderic Acid A (50μg/ml) and LPS (0.5μg/ml) for 24 hours significantly suppressed LPS-induced proliferation and activation of BV2 microglia, and promoted the polarization of microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype[5]. Treatment of MC3T3-E1 cells (induced with 1mM H₂O₂) and primary osteoblasts (induced with 250μM H₂O₂) with Ganoderic Acid A (5–80μM) for 24 hours significantly promoted osteogenic differentiation and mineralization nodule formation, and upregulated the protein expression of osteogenesis-related markers RUNX2, OPN, and β-catenin[6].

In vivo, intraperitoneal administration of Ganoderic Acid A (20–40mg/kg) 1 hour before Ovalbumin (0.1g) challenge in OVA-sensitized BALB/c mice significantly alleviated airway hyperresponsiveness and reduced the total number of inflammatory cells in bronchoalveolar lavage fluid[7]. Daily administration of Ganoderic Acid A (20mg/kg/d) via intraperitoneal injection or topical application for 6 days in Imiquimod (62.5mg per mouse)-induced psoriasiform dermatitis BALB/c mice significantly ameliorated skin erythema, thickening, and scaling, and lowered the Psoriasis Area and Severity Index (PASI) score[8].

References:
[1] Sui Q, Zhu C, Shi S, et al. Ganoderic acid A: an in-depth review of pharmacological effects and molecular docking analysis. J Ethnopharmacol. 2025 Jun 12;349:119868.
[2] Ma F, Wang J, Jiang W, et al. Ganoderic Acid A: A Potential Natural Neuroprotective Agent for Neurological Disorders: A Review. Int J Med Mushrooms. 2024;26(2):11-23.
[3] Zhang X, Huang S, Xu H, et al. Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer's disease. Front Pharmacol. 2025 Sep 19;16:1666082.
[4] Song Z, Wang C, Ding F, et al. Ganoderic Acid A Enhances Tumor Suppression Function of Oxaliplatin via Inducing the Cytotoxicity of T Cells. Anticancer Agents Med Chem. 2023;23(7):832-838.
[5] Jia Y, Zhang D, Yin H, et al. Ganoderic Acid A Attenuates LPS-Induced Neuroinflammation in BV2 Microglia by Activating Farnesoid X Receptor. Neurochem Res. 2021 Jul;46(7):1725-1736.
[6] Zhao J, Fan Y, Li H, et al. Ganoderic Acid A Prevented Osteoporosis by Modulating the PIK3CA/p-Akt/TWIST1 Signaling Pathway. Food Sci Nutr. 2025 Apr 14;13(4):e70177.
[7] Lu X, Xu C, Yang R, et al. Ganoderic Acid A Alleviates OVA-Induced Asthma in Mice. Inflammation. 2021 Oct;44(5):1908-1915.
[8] Xiao C, Chen J, Zhou X, et al. Ganoderic acid A alleviate psoriasis by inhibiting GSDMD-mediated pyroptosis. Tissue Cell. 2025 Dec;97:103078.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

BV2 microglial cells (murine microglial cell line)

Preparation Method

BV2 cells were cultured in DMEM high glucose medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C under 5% CO₂. Cells were treated with Ganoderic Acid A at 50μg/mL concurrently with LPS (0.5μg/mL) for 24 hours.

Reaction Conditions

50μg/mL; 24h

Applications

Ganoderic Acid A significantly suppressed LPS-induced BV2 microglial proliferation and activation. Ganoderic Acid A promoted the polarization of microglia from pro-inflammatory M1 to anti-inflammatory M2 phenotype.
Animal experiment [2]:

Animal models

Female BALB/c mice

Preparation Method

Mice were sensitized by intraperitoneal injection of 10mg Ovalbumin (OVA) + 1mg aluminum hydroxide in saline on days 1, 7, and 14. From day 21, they received daily OVA aerosol challenges (0.1g OVA in 10ml saline, 30min) for 7 days. Ganoderic Acid A (20 or 40mg/kg) was administered intraperitoneally 1 hour before each OVA challenge. Lung tissues and serum were collected after the final challenge for analysis.

Dosage form

20 or 40mg/kg; i.p.; Daily for 7 days.

Applications

Ganoderic Acid A significantly attenuated OVA-induced airway hyperreactivity (AHR), reduced inflammatory cell infiltration (eosinophils, lymphocytes, neutrophils) in serum and lung tissue, and decreased levels of Th2 cytokines (IL-4, IL-5, IL-13) and IgE in serum. Ganoderic Acid A also suppressed TLR4/NF-κB signaling pathway activation, as evidenced by reduced expression of TLR4, MyD88, p-NF-κB, and p-IκBα in lung tissues.

References:
[1] Jia Y, Zhang D, Yin H, et al. Ganoderic Acid A Attenuates LPS-Induced Neuroinflammation in BV2 Microglia by Activating Farnesoid X Receptor. Neurochem Res. 2021 Jul;46(7):1725-1736.
[2] Zhao J, Fan Y, Li H, et al. Ganoderic Acid A Prevented Osteoporosis by Modulating the PIK3CA/p-Akt/TWIST1 Signaling Pathway. Food Sci Nutr. 2025 Apr 14;13(4):e70177.

Produktdokumente (Product Documents)

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
81907-62-2
Chemischer Name
(2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
SMILES
CC(CC(=O)CC(C)C(=O)O)C1CC(C2(C1(CC(=O)C3=C2C(CC4C3(CCC(=O)C4(C)C)C)O)C)C)O
Summenformel
C30H42O7
Molekulargewicht
514.65
Löslichkeit
DMF: 5mg/mL,DMSO: 1 mg/mL,Ethanol: 3 mg/mL
Lagerung
4°C, away from moisture and light
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for Ganoderic Acid A

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%